MAP2K7 and cancer: As PBX3 activates MEK/ERK1/2 pathway to promote malignant phenotypes in some cancers [25], we hypothesized that PBX3 may promote GBM mesenchymal phenotype through MEK/ERK1/2 pathway mediated LIN28/let-7 axis activation.